Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant QL1706 With or Without Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
ChiCTR2600116629Phase 4Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of QL1706 in Esophageal Squamous Cell Carcinoma (ESCC) (4 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Pathological Complete Response. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600116629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116629.